Lannett starts phase I trial for insulin glargine biosimilar in South Africa

Biosimilars/News | Posted 02/08/2019 post-comment0 Post your comment

US generics maker Lannett Company (Lannett) announced on 5 June 2019 that it had started a phase I clinical trial of its candidate insulin glargine biosimilar.

Insulin 1 V13C03

Lannett has co-developed the product with its strategic alliance partners within the HEC group of companies (HEC), including China-based Yichang HEC Changjiang Pharmaceutical (Yichang) [1]. This trial, which is being carried out in South Africa, is part of the company’s effort to file a biosimilar biologics license application (BLA) with the US Food and Drug Administration (FDA).

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

Lannett/HEC’s trial is a single-centre, single-dose, double-blind, randomized, two-period crossover study. The aim of the trial is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of the candidate insulin glargine biosimilar versus the US-approved originator insulin glargine, Lantus. A total of 24 healthy male adult volunteers will receive a single subcutaneous dose. In addition, a secondary objective of the trial is to assess the safety profiles of the Lannett/HEC-insulin glargine compared to US-Lantus after single subcutaneous doses.

Lannett expects study results in September 2019.

Related article
Biosimilars of insulin glargine

1. GaBI Online - Generics and Biosimilars Initiative. Lannett to co-develop biosimilar insulin product with Chinese partner []. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 1]. Available from: 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: Lannett

comment icon Comments (0)
Post your comment
Related content
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010